(A) Combinatorial GSK126 and enzalutamide (Enz) treatment significantly
inhibited LNCaP cell growth and drug resistance. LNCaP cells were maintained in
DMSO, GSK126 (0.5uM), Enz (0.5uM), or both for 55 days. Cells were counted and
re-plated whenever needed, and accumulated cell numbers were determined. Data
shown are for one representative experiment of two.
(B and C) LNCaP (B) or C4–2B (C) cells were treated with DMSO,
Enz (1 μM for LNCaP and10 μM for C4–2B), EPZ (1 μM),
or both. Cell growth was measured with WST-1 reagent every 2 days. Data shown
are mean ± SEM of technical replicates from one representative experiment
of three.
(D and E) LNCaP (D) or C4–2B (E) cells were treated with DMSO,
Enz (1 μM for LNCaP and 10 μM for C4–2B), EPZ (1
μM), or both for 2 weeks, followed by 0.002% crystal violet staining to
assay colony formation. Data shown are technical replicates from one
representative experiment of three.
(F and G) Combinatorial Enz and EPZ treatment induced cell cycle arrest.
LNCaP (F) or C4–2B (G) cells were treated with DMSO, Enz (1 μM for
LNCaP and 10 μM for C4–2B), EPZ (1 μM), or both for 3 days,
followed by cell cycle analysis via flow cytometry with propidium iodide
staining.